Apeloa Pharmaceutical Co Ltd
SZSE:000739
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.04
18.07
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Operating Margin
Apeloa Pharmaceutical Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | CN |
| Market Cap | 18.8B CNY |
| Operating Margin |
10%
|
| Country | JP |
| Market Cap | 776 550.9T JPY |
| Operating Margin |
-83%
|
| Country | US |
| Market Cap | 755.8B USD |
| Operating Margin |
35%
|
| Country | UK |
| Market Cap | 440.4B GBP |
| Operating Margin |
3%
|
| Country | DK |
| Market Cap | 2.7T DKK |
| Operating Margin |
44%
|
| Country | US |
| Market Cap | 351.1B USD |
| Operating Margin |
28%
|
| Country | US |
| Market Cap | 251.8B USD |
| Operating Margin |
34%
|
| Country | CH |
| Market Cap | 200.1B CHF |
| Operating Margin |
32%
|
| Country | UK |
| Market Cap | 161.8B GBP |
| Operating Margin |
21%
|
| Country | CH |
| Market Cap | 171.5B CHF |
| Operating Margin |
31%
|
| Country | US |
| Market Cap | 151.5B USD |
| Operating Margin |
22%
|
Apeloa Pharmaceutical Co Ltd
Glance View
In the bustling heart of China's pharmaceutical industry, Apeloa Pharmaceutical Co Ltd stands as a testament to strategic innovation and adaptability. Established in 1989, the company has expertly navigated the ever-evolving landscape of pharmaceuticals, becoming a significant player in both domestic and international markets. Rooted in its commitment to research and development, Apeloa has built its success on a solid foundation of producing and selling active pharmaceutical ingredients (APIs) and finished pharmaceutical products. The firm's relentless focus on quality and efficacy has not only bolstered its reputation but also expanded its footprint across various therapeutic areas, including anti-infectives, cardiovascular, and central nervous system drugs. Apeloa's ability to anticipate health trends and pivot when necessary has enabled it to remain competitive, despite the fierce challenges of the industry. Apeloa's business model is underpinned by a robust integration of its R&D efforts with a diversified manufacturing and distribution network. This integration ensures that innovations are swiftly translated into marketable solutions, generating revenue streams that fund further research endeavors. Complementing its core pharmaceutical operations, Apeloa has ventured into the realm of contract development and manufacturing services (CDMO), providing end-to-end solutions for other companies looking to scale up their production without investing in their own infrastructure. Through strategic alliances and collaborations, Apeloa capitalizes on economies of scale and taps into new markets, amplifying its profitability and enhancing shareholder value. With a keen eye on sustainability and technological advancement, Apeloa continues to chart its course in the global pharmaceutical sector, balancing growth with a commitment to improving healthcare outcomes worldwide.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Apeloa Pharmaceutical Co Ltd's most recent financial statements, the company has Operating Margin of 9.7%.
You don't have any saved screeners yet
